Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Fisher Q3 "not too hot, not too cold"

This article was originally published in Clinica

Executive Summary

Thermo Fisher Scientific reported third-quarter sales of $3.19bn and adjusted earnings of $1.30 per share that were slightly ahead of analyst consensus of $3.18bn and $1.28 per share, respectively. The results represented revenue growth of 3% year-on-year and EPS expansion of 9% year-on-year. Jefferies analyst Brandon Couillard described the quarter as “not too hot, not too cold.” Meanwhile, Goldman Sachs’ Isaac Ro wrote: “We view this quarter as evidence that Thermo Fisher continues to execute on emerging market and end-market-specific growth strategies.” But he added: “However, we continue to believe the bull case rests on successful integration of the proposed Life [Technologies] transaction and thus we maintain our neutral rating” – Thermo agreed to buy Life for $13.6bn in April (www.clinica.co.uk, 16 April 2013). Mr Couillard, though, rates the company as “buy.” Thermo’s share price rose 2% to close at $97.48 on 23 October, the day it released the results.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel